Bacteriophage: Time to Re-Evaluate the Potential of Phage Therapy as a Promising Agent to Control Multidrug-Resistant Bacteria

Document Type : Review Article


Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran


Nowadays the most difficult problem in treatment of bacterial infections is the appearance of resistant bacteria to the antimicrobial agents so that the attention is being drawn to other potential targets. In view of the positive findings of phage therapy, many advantages have been mentioned which utilizes phage therapy over chemotherapy and it seems to be a promising agent to replace the antibiotics. This review focuses on an understanding of phages for the treatment of bacterial infectious diseases as a new alternative treatment of infections caused by multiple antibiotic resistant bacteria. Therefore,utilizing bacteriophage may be accounted as an alternative therapy. It is appropriate time to re-evaluate the potential of phage therapy as an effective bactericidaland a promising agent to control multidrug-resistant bacteria.


1. Tammelin A. Staphylococus aureus surgical wound infection; possibility of preventing wound infection by use of bacteriophages. Nature 1992; 22:26-31.
2. McNerney R, Traore H. Mycobacteriophage and their application to disease control. J Appl Microbiol  2005; 99:223–233.
3. Ackermann HW. Bacteriophage observations and evolution. Res Microbiol 2003; 154:245–251.                           
4.Higgins SE, Higgins JP, Bielke LR, Hargis BM.Selection and application of Bacteriophages for Treating Salmonella enteritidis Infections in Poultry. Int J Poult Sci  2007; 6:163-168.
5. Kutter E. Phage therapy: Bacteriophages as natural self-limiting antibiotics. AstraZeneca Research Foundation India, 2001.
6. Levin BR, Bull JJ. Phage Therapy revisited the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat  1996; 146:881-898.
7. Markoishvili K, Djavakhishvili N, Goderdzishvili M, Meipariani A, Chavchanidze Z, Tsitlanadze G, et al. PhageBioDerm - new prospects for treatment of wounds and trophic ulcers. Exp Clin Med  1999; 2:83-84.
8. Saunders ME. Bacteriophages in industrial fermentations. In:Webster R, Cranoff A.editors. Encyclopaedia of Virology. London: Academic Press;1994.116-121.
9. Soothill JS, Ayliffe GAJ. The efficacy of phages in the prevention of the destruction of pigskin in vitro by pseudomonas aeruginosa. Med Sci Res 1988; 16:1287-1288.
10. Kokgohn TA, Schrader J, Waller JJ, Schrader HS. Effects of stress on bacteriophage replication, School of Biological sciences university of, NE 2000; 68588-0343.
11. Balow A and Duerden BI. Topley and Wilsons microbiology and microbial infections.9th ed, Vol. 2.1998.
12. Pllitzer R.Cholera world health organization. Geneva. Switzerland. Available at: http;// T² phagetherapy/phagethea.1999.
13. Ross RP. Development of phage resisant starter strains infection control and hospital epidemiology. J Soci Health Epidemial 1999; 22:14-19.
14. Krueger AP, Northrop JH. The kinetics of the bacterium-bacteriophage reaction. J Gen Physiol 1931; 14:223.
15. Payne RJH, Jansen VAA. Phage therapy, the peculiar kinetics of self - replicating pharmaeuticals. Clin Pharmacol Ther 2000; 68:225-230.
16. Stencel Ch. Phages eyed as agents to protect against harmful E. coli. American Society for Microbiology News. 1999; 65: 666-667.
17. Thomas A, Lalitha MK., Jesudason MV, John S. Activity of bacteriophages. Am Arch 1983; 25: 211-214.
18. McKinstry M, Edgar R. Use of phages in therapy and bacterial detection, In Waldor MK, Friedman DI, Adhya S. (ed.), Phages: Their Role in Bacterial Pathogenesis and Biotechnology. ASM Press, Washington, DC. 2005 ; 430–440.
19. Little, JW. Lysogeny, prophage induction, and lysogenic conversion. In Waldor MK, Friedman DI, Adhya SL (ed), Phages: Their Role in Bacterial Pathogenesis and Biotechnology. ASM Press, Washington DC. 2005; 37-65.
20. Wagner PL, Waldor MK. Bacteriophage Control of Bacterial Virulence. Infect Immun 2002; 70:3985, 3985.
21. Emami SA, Tayarani- NaJaran Z, Sabouri Ghannad M, Khajeh Karamadini P, Khajeh Karamadini M. Antiviral activity of obtained extracts from different parts of cupressus sempervirens against Herpes Simplex Virus Type 1. Iran J Basic Med Sci  2009; 12:133-139.
22. Khajeh Karamoddini M, Emami SA, Sabouri Ghannad M, Alizadeh Sani E, Sahebkar A. Antiviral activities of aerial subsets of Artemisia as a medicinal plant against Herpes Simplex virus type 1 (HSV1) in vitro. Asian Biomed 2011;1:63-68.
23.  Sabouri Ghannad M, Majzoobi MM, Ghavimi M, Mirzaei M. Needlestick and sharp injuries objects among health care workers in Hamadan province, Iran (In press) 2012. J Emerg Nurs  DOI: 10.1016/j.jen.2011.01.009.
24. Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Gorski A. Bacterial viruses against viruses pathogenic for man? Virus Res 2005; 110:1–8.
25. Bradbury J. My enemy’s enemy is my friend. Lancet 2004; 363, 624–625.
26. Levin, B.R., Bull, J.J. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol  2004; 2:166–173.
27. Inal JM. Phag e therapy: a reappraisal of bacteriophages as antibiotics. Arch Immunol Ther Exp 2004; 51:237-244.
28. Stone R. Bacteriophage therapy: Stalin’s forgotten cure. Science  2002; 298:728–731.
29. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother 2001;45:649-659.
30. Weber-Dabrowska B, Mulczyk M, Gorski A. Bacteriophage therapy of bacterial infections: an update of our Institute‘s experience. Arch Immunol Ther Exp  2000; 48:547–551.
31- Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolyses, and antimicrobial peptides. J Appl Microbiol 2008; 104:1-13.
32. Garcia P, Garcia JL, Garcia E, Lopez R. Nucleotide sequence and expression of the pneumococcal autolysin gene from its own promoter in Escherichia coli. Gene 1986; 43:265-272.
33. Fischetti VA. Bacteriophage lytic enzymes: Novel anti-infectives. Trend Microbial 2005; 13:491-496.
34. Low LY, Yang C, Perego M, Osterman A, Liddington RC. Structure and lytic activity of a Bacillus anthracis prophage endolysin. J Biol Chem  2005; 280:35433-35439.
35. Fischetti VA. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 2005;13: 491-496.
36. Fishetti VA, Nelson D, Schuch R. Reinventing phage therapy: are the parts greater than the sum? Nat Biotechnol 2006; 24:1508-1511.
37. Leverentz B, Conway WS, Alavidze Z, Janisiewicz WJ, Fuchs Y, Camp MJ, et al.  Examination of bacteriophage as a biocontrol method for Salmonella on fresh cut fruit: a model study. J Food Protect 2001; 64:1116-1121.
38. Panthel K, Jechlinger W, Matis A, Rohde M, Rohde M, Szostak M, et al. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect Immune 2003; 71:109-116.
39. Ebensen T, Paukner S, Link C, Kudela P, de Domenico C, Lubitz W, et al. Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol  2004; 172:6858-6865.
40. Young R, Wang IN, Roof WD. Phage will out: strategies of host cell lysis. Trends Microbiol 2000; 8:120-128.
41. Remaut E, De Waele P, Marmeout A, Stanssens P, Fiers W. Functional expression of individual plasmid-encoded RNA bacteriophage MS2 genes. EMBO J  1982; 1:205-209.
42. Model P, Webster RE, Zinder ND. Characterization of Op3, a lysis-defective mutant of bacteriophage f2. Cell 1979; 18:235-246.
43. Arisaka F, Kanamaru S, Leiman P, Rossmann MG. The tail lysosyme complex of bacteriophage T4. Int J Biochem Cell Biol  2003; 35:16-21.
44. Leiman PG, Kanamaru S, Mesyanzhinov VV, Arisaka F, Rossmann MG.Structure and morphogenesis of bacteriophage t4. Cell Mol Life Sci  2003; 60:2356-2370.
45. Milller ES, Kutter E, Mosig G, Arisaka F, Kunisawa T, Ruger W. Bacteriophage T4 genome.  Microbiol Mol Biol Rev 2003; 67:86-156.
46. Rossmann MG, Mesyanzhiniov VV, Arisaka F, Leiman PG.The bacteriophage T4 DNA injection machine. Curr Opin Struct Biol  2004; 14:171-180.
47. Sabouri Ghannad M, Zamani A. The full length hepatitis C virus  polyprotein and interactions with the interferon-Beta signaling pathways in vitro. Iran Biomed J 2008; 12:23-24.
48. Embleton ML, Nair SP, Heywood W, Menon DC, Cookson BD,Wilson M. Development of a novel targeting system for lethal photosensitization of antibiotic-resistant strains of Staphylococcus aureus. Antimicrob Agent Chemother  2005; 49:3690-3696.
49.Yacoby I, Shamis M, Bar H, Shabat D, Benhar I. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob. Agents. Chemother 2006; 50:2087-2097.
50. Larocca D, Larocca D, Burg MA, Jensen-Pergakes K, Ravey EP, Gonzalez AM, et al.  Evolving phage vectors for cell targeted gene delivery. Curr Pharm Biotechnol 2002; 3:45-57.
51. Hanlon GW. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 2007; 30:118-128.
52. Joerger RD. Alternatives to antibiotics: Bactericins, Antimicrobial peptides and Bacteriophages. Poult Sci 2003; 82:640-647.
53. Alisky J, Iczkowski K, Rapoport A, Troitsky N. Bacteriophages how promise as antimicrobial agents. J Infect 1998; 36:5-15.
54. Slopek S, Durlakowa I, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A.  Results of bacteriophage treatment of suppurative bacterial unfections. III. Detailed evaluation of the results obtained in further 150 cases. Arch Immonol Ther Exp 1984; 32:317-335.
55.Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewick-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Arch Immonol Ther Exp 1983; 31:293-327.
56. Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewick-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I General evaluation of the results. Arch Immonol Ther Exp 1983; 31:267-291.
57. Slopek S, Kucharewick-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases. Arch Immonol Ther Exp 1985; 33:219-240.
58.Slopek S, Kucharewick-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in children. Arch Immonol Ther Exp 1985; 33:241-259.
59. Slopek S, Kucharewick-Krukowska A, Weber-Dabrowska B, Dabrowski M.Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Arch Immonol Ther Exp  1985;33:261-273.
60. Slopek S, Weber-Dabrowska B, Dabrowski M,  Kucharewick-Krukowska A.Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immonol Ther Exp 1987; 35:569-583.
61. Lood R., Collin M. Characterization and genome sequencing of two Propionibacterium  acnes phages displaying pseudolysogeny. BMC Genomics  2011;12:198.
62. Cheng CM, Wang HJ, Bau HJ, Kuo TT. The primary immunity determinant in modulating  the lysogenic immunity of the filamentous bacteriophage. J Mol Biol 1997; 287:867-867.
63.Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Uijhara T, Kuroda M, et al. Bacteriophage therapy: a revitalized therapy against bacterial infection diseases. J Infect Chemother 1997; 11:211-219.                             
64. Skurnik M, Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol  2006;296:5-14.
65. Khajeh Karamoddini M, Fazli-Bazzaz BS, Emamipour F, Sabouri Ghannad M, Jahanshahi AR,  Saed N, et al. Antibacterial efficacy of lytic bacteriophages against antibiotic-resistant Klebsiella species. Scientificworldjournal  2011; 11:1332-1340.
66. Bernhardt TG, Wang I, Struck DK, Young R. A protein antibiotic in the phage Qβ virion: diversity in lysis targets. Science 2001; 22:2326-2329.
67. Bernhardt TG Wang, I, Struck DK, Young R..The lysis protein E of φX174 is a specific inhibitor of the MraY-catalyzed step in peptidoglycan synthesis. J Biol Chem 2001; 276; 6093-6097.
68. Courchesne NM, Parisien A, Lan CQ. Production and application of bacteriophage and bacteriophage-encoded Lysins. Recent Pat  Biotechnol  2009; 3:37-45.
69. Petty NK, Evans TJ, Fineran PC, Salmond GPC. Biotechnological exploitation of bacteriophage research. Trends  Biotechnol  2006; 25:7-15.
70. Skurnik M, Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol 2006; 296:5-14.